Stock & Company Details
Iovance Biotherapeutics Inc $IOVA
Price:
N/A
N/A
453M
$6B
52 Week High:
N/A
10 Day Average Volume:
N/A
-18.46
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
IOVA technical indicators
Latest Iovance Biotherapeutics Inc (IOVA) indicator readings as of 2026-10-09.
IOVA's 14-day RSI is 73.2, in overbought territory. At $14.62 it is trading 191.8% above its 200-day moving average of $5.01, and above its 50-day average of $9.15. Price sits near the upper Bollinger Band ($8.00 to $15.82). ADX reads 59.1, indicating a trending market.
IOVA backtested strategy results
How 4 rule-based strategies performed on Iovance Biotherapeutics Inc (IOVA) over recent history, last backtested 2026-10-07. Select a strategy to plot its trades on the chart above. Past performance does not predict future results.
| Strategy | Equity curve | Return | Win rate | Trades | Max drawdown |
|---|---|---|---|---|---|
| Oversold Bounce Mean reversion Buy when RSI falls below 30 (oversold), sell when it climbs above 70 (overbought). | -66.4% | 19% | 21 | -89.1% | |
| Momentum Crossover Momentum Buy when MACD turns positive (crosses above zero) and RSI confirms momentum above 50; sell when MACD falls back below zero. | -68.2% | 19% | 31 | -84.6% | |
| Volatility Breakout Volatility Buy when price closes above the upper Bollinger Band, sell on reversion to the 20-day average. | +103.0% | 41% | 22 | -34.4% | |
| Strong-Trend Pullback Trend + timing In strongly trending stocks (ADX above 25), buy short-term dips (Stochastic below 30) and sell into overbought (above 80). | +44.9% | 43% | 30 | -54.3% |
Overview
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Finance Bot
Ask your questions
Start by typing a question below.
